Editorial: Surgical treatment of malignant peritoneal mesothelioma: Past, present, and future

Annals of Surgical Oncology

Volumn 17, Issue 1, 2010, Pages 21-22

  Alexander Jr , H Richard ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CISPLATIN; DOXORUBICIN;

ADVANCED CANCER; CANCER RISK; CANCER SURGERY; CYTOPATHOLOGY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DRUG MEGADOSE; EDITORIAL; HUMAN; HYPERTHERMIC THERAPY; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERITONEUM MESOTHELIOMA; PROGNOSIS; RECURRENT CANCER; SURGICAL TECHNIQUE; TUMOR RECURRENCE; MESOTHELIOMA; NOTE; PATHOLOGY; PERITONEUM TUMOR;

HUMANS; MESOTHELIOMA; PERITONEAL NEOPLASMS;

EID: 74649083926     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0763-3     Document Type: Editorial

References (9)

1. CG Moertel 1972 Peritoneal mesothelioma Gastroenterology. 63 346 350 1:STN:280:DyaE383ksVaktw%3D%3D 4558717
2. M Borow A Conston LL Livornese, et al. 1967 Mesothelioma and its association with asbestosis JAMA. 201 587 591 10.1001/jama.201.8.587 1:STN:280:DyaK3M3lvFGqtw%3D%3D 5006760
3. MK Samson LP Wasser EC Borden, et al. 1987 Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study J Clin Oncol. 5 86 91 1:STN:280:DyaL2s7htFKqsQ%3D%3D 3543239
4. AP Chahinian K Antman M Goutsou, et al. 1993 Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B J Clin Oncol. 11 1559 1565 1:STN:280: DyaK3szivFGjsw%3D%3D 8336195
5. R Govindan RA Kratzke JE Herndon, et al. 2005 Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B Clin Cancer Res. 11 2300 2304 10.1158/1078-0432.CCR-04-1940 1:CAS:528: DC%2BD2MXisFaju7k%3D 15788680 (Pubitemid 40490190)
6. R Hassan AT Remaley ML Sampson, et al. 2006 Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer Clin Cancer Res. 12 447 453 10.1158/1078-0432.CCR-05-1477 1:CAS:528:DC%2BD28XmtlKisw%3D%3D 16428485 (Pubitemid 43166134)
7. K Antman R Osteen K Klegar, et al. 1985 Early peritoneal mesothelioma: a treatable malignancy Lancet. 2 977 981 10.1016/S0140-6736(85)90526-4 1:STN:280:DyaL28%2FjvFamsA%3D%3D 2414612
8. HR Alexander N Hanna JF Pingpank 2007 Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma Cancer Treat Res. 134 343 355 1:STN:280:DC%2BD2svhsVSquw%3D%3D 17633065
9. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph-node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2009.